Stereotaxis (STXS) Projected to Release Earnings on Monday

Stereotaxis (NYSEAMERICAN:STXS) will likely be releasing its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect Stereotaxis to post earnings of ($0.06) per share and revenue of $9.24 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

Stereotaxis Stock Performance

Shares of STXS stock opened at $2.16 on Monday. The stock has a fifty day moving average price of $2.34 and a 200 day moving average price of $2.61. The stock has a market cap of $201.57 million, a PE ratio of -7.71 and a beta of 1.38. Stereotaxis has a 1 year low of $1.54 and a 1 year high of $3.59.

Institutional Trading of Stereotaxis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Equitable Holdings Inc. acquired a new position in Stereotaxis during the 4th quarter worth $46,000. Deutsche Bank AG raised its stake in shares of Stereotaxis by 10.6% in the 4th quarter. Deutsche Bank AG now owns 51,584 shares of the company’s stock valued at $119,000 after purchasing an additional 4,948 shares in the last quarter. Boothbay Fund Management LLC bought a new position in shares of Stereotaxis during the third quarter worth about $54,000. Virtu Financial LLC acquired a new position in Stereotaxis in the third quarter worth about $70,000. Finally, Man Group plc acquired a new position in Stereotaxis in the third quarter worth about $142,000. 45.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Roth Mkm reaffirmed a “buy” rating and set a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 12th. Citigroup began coverage on shares of Stereotaxis in a report on Tuesday, December 16th. They set an “outperform” rating for the company. UBS Group set a $4.00 price target on shares of Stereotaxis in a report on Wednesday, November 5th. Finally, Citizens Jmp started coverage on shares of Stereotaxis in a research report on Tuesday, December 16th. They issued a “market outperform” rating and a $4.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $4.00.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.